In This Section

A Comprehensive Cancer Center Designated by the National Cancer Institute

Cytometry and Antibody Technology (CAT) Facility

Scientific Director: Anne Sperling, PhD
Technical Directors: Ryan Duggan, BA, Flow Cytometry Subcore (FCS), Carol McShan, BA/BS, Fitch Monoclonal Subcore (FMS)

(Read an article about this core in Pathways to Discovery)

The CAT Facility provides investigators with all of the tools necessary to measure the properties of cells and their products. The Fitch Monoclonal Subcore (FMS) develops the reagents used to label the cells (novel monoclonal antibody production, purification of existing monoclonals, and fluorescently-coupled antibodies), whereas the Flow Cytometry Subcore (FCS) provides the technology and staff expertise to use these reagents for experimental measurements (flow cytometers, image cytometers, and cell sorters). Antibody technology and its usage have evolved concurrently with flow cytometry and has become the dominant tool for the identification and classification of cells and cellular products. The CAT Facility provides instrumentation and antibodies for the analytical detection of subcellular components and proteins using a range of fluorescence and non-fluorescence-based detection technologies. Further, the CAT Facility maintains an Antibody/Hybridoma Bank that provides commonly-used, highest-quality purified antibodies, pre-titered conjugated antibodies for flow cytometry, and hybridoma cell lines.


    • Bench-top cytometry analysis
    • Cell sorting
    • Novel monoclonal antibody production
    • Detection assay development
    • Bioreactor production
    • Development of novel fluorescence-based detection assays and applications
    • Antibody purification and conjugation
    • Hybridoma bank